Researcher Profile Form First National Pediatric Brain Tumor Research Meeting March 9, 2025 - Jerusalem
Researcher: Peter Siman
Current Role & Affiliation
Title/Position: CEO, CSO & Co-Founder of IntraGel LTD
Email: peter@intra-gel.com
Phone: 0535830767
Peter is the co-founder, CEO, and CSO at IntraGel Therapeutics, a clinical stage pharmaceutical company in the field of oncology. IntraGel Therapeutics specializes in developing safe, localized, and long-acting treatments for solid tumors.
Current Projects Related to Pediatric Brain Tumors
IntraGel designs solution for localized intra-tumoral injectable drug delivery system, SRGel, that extends the release and efficacy of most anticancer medications.
Collaboration Interests
Use of IntraGel’s technology in new forms of cancer
Keywords
Polymer Chemistry ,Research and Development , Management ,Business Development, Business Management
Recent Relevant Publications
1. Ben-David E, et.al. Characterization and Evaluation of Injectable Biodegradable Polymer Multimodality Radiologic Markers in an In Vivo Murine Model. Biomacromolecules. 2022 Apr 11;23(4):1672-1679. doi: 10.1021/acs.biomac.1c01570. Epub 2022 Mar 31.
Brief Bio
Dr Siman is holding B.Sc. and M.Sc. from the Department of Chemistry at the Hebrew University of Jerusalem, Ph.D. in chemistry from the Department of Chemistry at Ben-Gurion University of the Negev, and postdoctoral training program at the University of California – Berkeley (UCB).With a background in multidisciplinary chemistry and materials science, Peter possesses a unique and critical thinking approach. In addition to his role at IntraGel Therapeutics, he serves as a freelance consultant, providing expertise to various companies and startups in the areas of polymers, medicinal polymers, composites, and polymer development.
